Clinical Research Directory
Browse clinical research sites, groups, and studies.
Description of the Ability to Learn How to Handle Inhaler Devices in COPD
Sponsor: University Hospital, Bordeaux
Summary
Chronic Obstructive Pulmonary Disease (COPD) is the fourth leading cause of death in the world and further increase in its prevalence and mortality has been predicted. Currently, the main long-term treatments are the long-acting beta-2 agonist, indacaterol, salmeterol and the anticholinergic drug, tiotropium and glycopyrronium, used alone or in combination: * long-acting beta-2 agonist with corticosteroid (e.g. salmeterol/fluticasone), * long-acting beta-2 agonist with anticholinergic (e.g. indacatetrol/glycopyrronium). These drugs are delivered to the lung using different inhaler devices such as Breezhaler ®, Handihaler® and Diskus®.
Key Details
Gender
All
Age Range
40 Years - Any
Study Type
INTERVENTIONAL
Enrollment
24
Start Date
2017-01-10
Completion Date
2019-03-08
Last Updated
2026-05-14
Healthy Volunteers
No
Interventions
Seretide® Diskus® 500/550 μg
Every day during 7 days
Ultibro® Breezhaler® 110/50 μg
Every day during 7 days
Spiriva® Respimat® 2,5 μg
Every day during 7 days
Locations (1)
CIC-P - Centre François Magendie - G3 - Hôpital Haut-Lévêque
Bordeaux, France